Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Dr. Brady has a Phd
Gerald Commissiong has a BS in financial engineering - looks where that's gotten AMBS/TOMDF SH's
and trouble from the Santa Clara County DA's office for providing alcohol to minors while on campus
http://www.greekchat.com/gcforums/showthread.php?t=47403
Paxlovid is FDA approved
Tollovir can't get EAU even though Gerald Commission indicated Greece & Israeli EAU would be sought
what's wrong with this picture...?
SMH - nuff said
MOO pathetic
why don't you want to tweet DB himself ...?
go get your question answered directly from the Source...!
that would be the most practical thing to do - and with no 3rd party - eh...?
makes me wonder - were you the type of kid that made others do your homework for you...?
gheeze Louise - talk about Cra Cra making...
SMH - nuff said
BAF MONI...!
this ain’t Calculus you know…
SMH - way too much drama
suggestion - chillaxa and enjoy the ride
momo $MONI
sorry if you are not privileged to have DB on speed dial to ask directly
however, your local grammar school offers math tutoring after hours
I'd start there...
Lock & Load sir - MONI going to surprise...!
MOO party
damn…!
nice picks | nice charts….
BAF MONI
damn ….!
nice charts
BAF MONI
who knows...?
DB's record = +4830%
soon to be = +6,000%
DB puts reputation on-the-line - backs up words in writing...!
DB views to date (yellow highlight) = 10,900 - Credibility high
Redspeed followers = 69 - Credibility shot
I'll side with DB anytime - anywhere - anyplace - hands down...!
next week DB and MONI momo will splode
DB's can of Knuckles Brand "WHOOP ASS"coming Chucklefuck's way...!
SMH - nuff said - BAF MONI...!
AJMHO
have you checked the Accum/Dist line lately….?
no need to answer - it was a rhetorical question…
BAF MONI …!
Uh oh
no place to run no place to hide …
for the Chuckleface name thrower - that is….!
LMAO
$MONI
so much for LymPro
and the German Policies Approval List before issuing the summer 2022 test results:
https://www.biospace.com/article/releases/todos-medical-announces-enrollment-complete-for-confirmatory-cohort-of-lympro-alzheimer-s-blood-test-clinical-validation-trial-vs-amyloid-pet/
I guess Mr Redsputter - Back Office TOMDF stock pumper, shill & tout could say its "crickets" for LymPro....
SMH nuff said...
MOO pathetic
If you truly understood this security, you would not be making such a sophomoric statement.
There is no full management team “squarely seated” at MONI’s helm at present.
This is a merger in transition, with ownership in the same transition phases.
Scott Hamolin is the new CEO coming in.
Frank Attovani is MONI’s former owner going out.
While the process has been laboriously long and updates few and far between…
that does not inferred that action is not underway - it is - and it continues to head towards final completion.
SMH - nuff said
BAF MONI…!
Lympro - everything everywhere all at once
LymPro Heading into 2014: Shifting the Diagnostic Paradigm in Alzheimer’s
November 4th, 2013
One thing that is 100% guaranteed as we transition into the execution phase of the Affordable Care Act’s implementation is that we have little certainty what US healthcare will look like in the second half of 2014 when we expect LymPro to be commercialized. The evolving regulatory and reimbursement landscape is staggeringly complex in this new age of healthcare in the United States. It is being further complicated by the uncertainty created by political gamesmanship and very legitimate concerns that some Americans are beginning to experience as new rules start altering the way healthcare has historically been delivered. From our perspective, the addition of new rules encouraging preventative measures, including diagnostic tests at key points in life, could be tremendously valuable to human health and to our bottom line. One thing that will remain throughout all of the likely policy shifts of the future is the fact that Alzheimer’s disease (AD) costs the nation $400B per year, and is expected to grow to $1.2T (yes, trillion) by 2050; this represents 10% of all healthcare costs in the US (which also accounts for 2% of GDP). Five million people in the United States alone have been diagnosed with AD, with an additional 400,000 patients being diagnosed every year, and I am absolutely certain AD does not care who the President is or what insurance coverage you carry; it will continue to wreak devastation on the population until new products can be brought to market to help defeat it. In 2014, a fact that will remain is that the nationwide shift to a definitive diagnosis of AD at an earlier stage than is currently standard will have a dramatic effect on the manner in which patients and their families are able to plan for their futures. It would empower patients to plan for the rest of their lives and potentially begin enrolling earlier in disease progression in trials with drug companies to try new approaches that could help slow, stop, and/or reverse the clinical course of this devastating disease; and potentially significantly alter AD’s overall cost to the US and world economy.
The LymPro Test® license agreement we executed in the fourth quarter of 2012 that was the centerpiece of our business development strategy of the last 12 months is turning out to be a tremendously beneficial transaction for Amarantus. With the analytical performance of the assay now established, and as we prepare the analytical and clinical performance packages necessary to support the commercial launch of LymPro Test® in the second half of 2014 as a Laboratory Developed Test (LDT) under the Clinical Laboratory Improvement Amendments (CLIA), we are continuing to execute on our strategy of recruiting highly skilled and experienced personnel to lead the charge to put LymPro front and center in the effort to help shift the diagnostic paradigm of AD. The Company believes LymPro could ultimately become the standard diagnostic test for AD in the industry if properly developed, and we are diligently working to actualize this by focusing our efforts on overcoming very early on the challenges that have plagued other companies in the space. The Custom Technology Team at Becton Dickinson has certainly earned the reputation they have garnered in the industry, as they are able to deliver outstanding results on time and on budget, and have the requisite experience in developing Flow Cytometry assays to understand how put this technology in the appropriate parameters for commercialization. We could not have a better team to work with in this regard. Our Advisors Adam Simon, PhD and Colin Bier, MD have a wealth of practical experience in AD diagnostic development, and both believe in LymPro’s diagnostic and prognostic potential. We are in the process of adding additional regulatory and reimbursement expertise to the team to further cement the LymPro development plan through to FDA approval and unrestricted nationwide Centers for Medicare & Medicaid Services (CMS) reimbursement.
Beyond the product development aspects of the assay, our team is beginning to work on defining the appropriate pricing strategy for LymPro once it is launched, as well as establishing realistic cost of goods sold (COGS) at time of launch, and what type of economies of scale would be gained over time as we work to ramp up distribution of LymPro from initial launch to mass distribution. If the launch of the Affordable Care Act website is any guide, we know the importance of initial product launch in gaining credibility in the marketplace. As we build the launch strategy, we will be seeking to sequentially move LymPro from a research tool, to a screening test as part of the standard diagnostic paradigm, ahead of moving to more expensive or invasive diagnostic tests such as PET and CSF, and ultimately as a confirmatory diagnostic test without the need for PET or CSF. As we work through this shift in the diagnostic paradigm, working closely with key opinion leading physicians in the space will be paramount, and we are currently negotiating with leading clinical sites to provide this support. We have been working on numerous case scenarios where we establish sales forecasts, and all of them have us reaching the $500M per year in peak sales if LymPro becomes the gold standard in the industry. However, the timeframe to get to that colossal milestone can vary greatly depending on certain variables, most notably viable therapeutic interventions.
While there are certainly a number of clinical utility (value to payer vs. price) arguments to be made for widespread adoption of a blood test for AD as a standalone product that could see LymPro become an attractive profit center able to support other activities within the Company, none is more powerful for driving rapid widespread adoption than a LymPro diagnosis leading to a lifestyle-improving treatment regimen. Several companies have spent several billions of dollars over the last decade trying to develop meaningful new treatments for AD, with little success. However, our clinical understanding of AD has advanced tremendously as a result of these investigational efforts. One of the things that we have learned from these studies is that amyloid plaques have been correlated to pre-clinical and early-stage disease progression but not clinical progression, whereas it is now being hypothesized that the tau tangles that are also a hallmark of clinical AD are more directly correlates with clinical progression. At a presentation at the 2nd Annual European Investing and Partnering Summit in Helsinki, Finland, I discussed the emerging link between LymPro’s mechanism of identifying aberrant neuronal cell cycle re-entry (CCR), and CCR’s direct link to amyloid beta and tau. We also heard presentations from several companies, including Genentech, confirming this understanding of amyloid and tau within the context of AD. We are continuing to build on our understanding of the cytokine cascade that occurs in aberrant neuronal CCR, and whether this phenomenon is the result, or the cause of amyloid plaques and tau tangles.
Regardless of whether CCR is causative or resulting, the fact that LymPro potentially identifies this activity pre-clinically suggests that it could be an ideal tool to identify patients that should be enrolled in trials targeting the earliest stages of the disease. This could ultimately lead to LymPro’s use as a companion diagnostic to screen for patients that would be put onto drug therapy once those therapies are approved, further driving LymPro sales and demonstrating its value to CMS and therapeutic companies from a clinical utility perspective. Unlike Amyvid, Eli Lilly & Co.’s amyloid PET imaging agent, or GE’s recently approved Vizamyl that also identifies amyloid plaques, LymPro is measuring an underlying mechanism specific to AD in a manner that will be relatively simple and reasonably priced from the patient and payer perspective. We expect the initial target market for LymPro to be pharmaceutical companies investigating therapeutics in AD, key opinion leading physicians seeking to establish new diagnostic paradigms in AD, and individuals seeking to better understand whether Alzheimer’s could be the a cause of their cognitive impairment. Once we establish sufficient data through tracking commercial sales cases and in well-controlled clinical studies, we expect to evaluate the reimbursement strategy at the state and national levels. While reimbursement of an expensive and involved diagnostic processes for AD such as PET have not yet met the criteria necessary to demonstrate widespread clinical utility for CMS (other than for research purposes), the reimbursement case for a simple blood test that will be significantly less expensive than PET imaging is likely to be more attractive, even without related treatments. Certainly, while we gather the clinical utility data to support LymPro’s ultimate commercial price, research reimbursement could prove to be a boon for Amarantus to underwrite much of the data gathering exercise, and we are looking closely at CMS’ decision on Amyvid as a framework for planning out LymPro’s future development. This may be an accelerated route for reimbursement for LymPro and one that would put us in a position to better understand CMS’ framework for AD reimbursement decision-making and build the clinical utility case for ultimate nationwide reimbursement as a standalone diagnostic product. The same trials that would drive US reimbursement would also be applicable for European reimbursement.
Late-stage, amyloid targeting therapeutics currently being pursued by companies such as Eli Lilly and Genentech are focused on very early treatment of small subsections of the AD population that have genetic predispositions to AD (making these trials most likely to confirm or disprove the amyloid drug target hypothesis in AD). These will likely help shape the market potential for LymPro as we move forward; and we have hope for amyloid treatments for early-stage AD. In particular, the Genentech trial gives hope as it is being conducted as a registrational trial, which means that even though the patient population with this specific predisposition to AD is small, proof will have been convincing enough for approval at the FDA that: 1. pre-AD leads directly to AD, 2. an AD therapeutic can slow or stop the transition from pre-AD to AD in this small population, and more importantly for LymPro, 3. the need for a diagnostic test that can identify early AD in a much broader sample of the population will become absolutely paramount if the trial is successful in order to drive the label-expanding exercise that would certainly follow the initial success and drive sales to a much broader swatch of AD patients. Additional trials, such as the Phase III study currently being conducted by TauRx, are building upon the newer tau hypothesis in AD which appears to be correlated more directly with clinical symptom progression. These new studies could also help build the case for LymPro’s clinical utility in the marketplace from a time to market standpoint; the sooner drug therapies reach the market, the more rapidly the value of a simple blood test such as LymPro would increase. As we build our clinical performance program into commercialization over the next several months to ultimately establish clinical utility, we are squarely focused on ensuring that we develop the data sets in a manner that will position LymPro for widespread adoption regardless of which therapeutic category is successful. The manner in which we collect the data and correlate a positive or negative LymPro result with gold standards in the AD diagnostic space, such as PET of CSF markers, will be paramount to streamlining our clinical utility package to support the widespread medical use of LymPro. We are looking for innovative ways to collaborate with groups who are already working with these other diagnostic modalities in order to reduce the cost of gathering rock solid clinical utility data and expect to update the marketplace in this regard once finalized.
As we build out LymPro in AD, we are also aware that it may have applications for the identification of traumatic brain injury (TBI) patients who may progress to Chronic Traumatic Encephalopathy (CTE) based on the same aberrant CCR hypothesis. With the recent settlement between the NFL and a number of players surrounding concussions and related symptoms, the focus is now shifting from legal matters to more important ones involving treatments, diagnostics and improving patient outcomes. We believe that Amarantus could play an essential role in both molding the tone of the debate and coming up with solutions, such as LymPro, MANF and others we have identified and are helping to move along, that could play a major role in making contact sports safer for athletes both in the short and long term. We will be making additional announcements in this direction shortly, but are now more excited than ever with our partnership with Brewer Sports around the Coalition for Concussion Treatment (#C4CT). Heading into the Super Bowl in New York in early 2014, we expect an increased focus in this direction and Amarantus will be there front and center with our partners to identify the best opportunities for meaningful advancement. As we build out our diagnostic franchise, we are keen to keep an eye towards building shareholder value and improving patient outcomes. We believe these two things go hand and hand, and we certainly believe AD is an indication where there is massive potential for both. After exhaustive diligence of the competitive landscape, we see no reason why LymPro could not be first and best in the marketplace, so the focus is turning squarely on execution and continuing to deliver on the milestones we have set out.
*We will continue to advance LymPro towards key value inflection points that we believe will put the Company in a position to up-list to a national stock exchange in 2014. We are currently putting in place the necessary regulatory and corporate governance components required to list on a national exchange, and intend to update the marketplace regarding these matters as they are executed upon. The recent success of several public offerings on national stock exchanges has certainly increased our confidence that Amarantus is headed in the right direction and up-listing to a national exchange will unlock the incredible value inherent in our pipeline, business strategy and management team. To that end, we are tying up all potential ‘loose-ends’ to ensure that when we take that fateful step to up-list, we do so from a position of strength allowing our shareholders to benefit from the increased investor visibility that will be garnered from a national exchange listing.
While being strong may not be the only predictor of survival or success, it certainly helps. The team at Amarantus is growing stronger by the day, and we are building the Company to be the victors in the marketplace when the dust settles. Our recent move into Janssen Labs @QB3 will dramatically increase the profile of the Company, as we are the only public company in the incubator, and will get direct access to invaluable advice from key personnel in the industry, as well as exposure to other innovative companies and scientists working in similar areas.
Thank you for taking the time to read this blog and I look forward to updating you on the advancement of Amarantus across diagnostics, therapeutics and discovery in the near future.
Warmest Regards,
Gerald E. Commissiong
President & CEO
_______________________________________________________________________________________________________________________________________________________________
AAIC 2014 - Understanding the Data Being Presented - LymPro Test Ver. 2
July 9th, 2014
Over the last 24 hours I have received several emails and inquiries from investors as it relates to understanding exactly what data will be presented by Amarantus at the Alzheimer’s Association International Conference on the 14th and 15th of July in Copenhagen. As a result, today I am providing a summary of the data we will be presenting, why we’ve chosen to present it this way, and what additional data will be presented at our #C4CT Summit on July 31st at the United Nations (www.c4ctsummit.com):
1. Clinical Performance – Data will be presented from in summary form from all of the published data sets on LymPro (Steiler et al, 2001 and 2012), as well as new data from a study conducted by Memory Dx (f/k/a Provista Life Sciences) in the winter of 2008. The primary focus will be on conditions for the LymPro assay used in this new study, which formed the basis for our acquisition of Version 2 of LymPro in May of this year from Memory Dx. The data, which has never been presented in any public forum, is from a 44 patient study that was tightly controlled several months prior to Memory Dx running into technical difficulties in the fall of 2008. The study evaluated Alzheimer’s patients, aged matched healthy controls, as well as vascular dementia and Parkinson’s disease dementia (together ‘other dementias’). The Company believes this Version 2 may improve upon certain critical principles established in Version 1, and make the diagnostic value of LymPro even higher than originally described;
2. Analytical Performance – Data will be presented from studies conducted at Becton Dickinson (BD) in 2013 and 2014 that form the basis of the current analytical performance package. The data, standard operating procedures (SOPs) and other proprietary assay parameters will facilitate transfer of the assay into our prospective partner’s laboratory for the purpose of commercialization under CLIA, a process BD has executed with our target partner several times. In this poster, we will also take into account scientific advancements in the field that underscore the analytical validity of cell cycle measurements for Alzheimer’s disease, most notably stage-independence of cell cycle and relationship between cell cycle, tau tangles and amyloid depositions;
3. Longitudinal Clinical Performance – Data will be presented from a follow-up patient record study of the Version 2 Clinical Performance Data mentioned above. We believe this data is the most scientifically relevant as it will add significant validity to the original Version 2 data by giving us an assessment of the change in physician’s diagnosis over time as compared to the LymPro score. Of highest potential value is whether LymPro was able to identify pre-symptomatic patients who would eventually progress to symptomatic AD (false-negatives).
Taken together, we believe this data provides a comprehensive perspective on LymPro. In addition, the Company will be presenting data at our July 31st #C4CT Summit regarding a bridging study in which the Company is comparing Version 1 and Version 2 of LymPro in a head to head study of 72 patients (AD vs. healthy control) to independently reproduce findings from the 2008 Clinical Performance study regarding greater separation in the different cohorts in Version 2 vs. and Version 1. Combined, these four data sets could provide a strong rationale for moving solely to Version 2 of the assay which the Company believes would add tremendous value to LymPro’s diagnostic value.
Dr. Louis Kirby (a recent Advisory Board addition, so not mentioned in the poster submissions which occurred in February), who is a Board-certified neurologist with a specialty in Alzheimer’s and has been the principle investigator on over 400 trials, will be present to assist in the question and answer sessions, and will be presenting data at #C4CT on behalf of the Company. We will also have a strong corporate presence, with our diagnostics, business development, regulatory and finance team onsite at AAIC and #C4CT. We believe AAIC represents a golden opportunity to let the scientific community know about LymPro’s advancements and that it will be on the market later this year (we are finding in our business development outreach that many research groups liked the concept in the Provista days, however lost track post-2008).
We have all seen reports in the media this week about a UK-based Proteomics Sciences blood test for Alzheimer’s in development, as we did several months ago regarding a lipid-based blood test from Georgetown. The reason there is such an explosion in media interest for Alzheimer’s blood tests is because everyone recognizes the massive unmet need. We would like to underscore that it is good for the field that multiple groups are moving on this concept because it reinforces that it is scientifically feasible to accomplish, and strengthens our case. We believe our approach of assessing an underlying aspect of disease biology and preparing for commercial-launch ahead of a major media push is the correct path so we can maximally capitalize on potential media attention, not only by an increase in the number of interviews I conduct, but most importantly by product sales. We continue to believe LymPro is likely superior to other non-disease biology related tests, and that our advantages are significant:
1. We will be first to market by years. This will allow us to appropriately establish a market for LymPro ahead of others and make LymPro the standard within the space;
2. Both the Proteomics and Georgetown based tests were identified through an iterative process, with no direct relation to disease biology, whereas LymPro is measuring a specific aspect to disease biology. This significantly improves the potential utility of LymPro as a companion diagnostic, which will ultimately be a massive value driver for any Alzheimer’s blood test;
3. LymPro has over a decade of scientific validity within the context of the cell cycle hypothesis in Alzheimer’s, with reproducibility of this finding by several independent academic group. The hypothesis has recently been expounded upon by new findings that form a rational basis to explain tau tangle formation and amyloid depositions, a huge advancement for the field. Targeting cell cycle is emerging as a new therapeutic target with significant potential because it is immediately attractive to drug developers who have anti-amyloid and anti-tau drugs as they may have activity within cell cycle, thereby furthering the rationale for pharmaceutical companies’ already massive investment. What is ultimately missing for cell cycle to takeoff as a significant ‘drugable’ target is a diagnostic that can identify cell cycle early-on in the disease process, and LymPro can fill that need as it is the most advanced cell cycle diagnostic test.
In summary, we are excited to be presenting the Company’s first data sets on LymPro to the scientific community at AAIC. We have noted recent interest in Alzheimer’s blood diagnostics from competing labs, and continue to believe that we have the most advanced diagnostic blood test in terms of commercial readiness due to the rigor we endeavored upon with Becton Dickinson, and scientific fundamentals. We are well positioned to transfer LymPro to a commercial lab where our protocols will be implemented according to commercial standards under CLIA. We believe the data sets presented next week will provide the basis for initial LymPro sales to pharmaceutical companies and Key Opinion Leaders who are continually seeking to improve their diagnostic paradigms. Ultimately, we intend to gather data with our partners on several thousand patients through strategic collaborations and commercial sales (as all other prospective tests will have to do), which will ultimately allow for submission to the FDA for approval. The data will be produced in a commercial setting, adding significant validity to the results from an FDA standpoint (In Vitro Diagnostics regulations are quite stringent) and providing the marketing credibility needed to accelerate sales along the way. We believe the future for LymPro is very, very bright and are excited to soon be offering new options to physicians and patients struggling to cope with the massive burden that Alzheimer’s presents.
Thank you for taking the time to read this blog. This is an exciting time for Amarantus as we look forward to the coming days at AAIC and especially to our #C4CT Summit at the United Nations. We invite all interested parties to sign up to attend #C4CT Summit at http://www.c4ctsummit.com/registration/.
Warmest Regards,
Gerald E. Commissiong
President & CEO
______________________________________________________________________________________________________________________________________________
Initiating Studies for CLIA Launch at ICON Central Lab’s
Sept. 2th, 2014
This morning we announced the initiation of CLIA-enabling studies at Icon Central Laboratories, a CLIA-certified laboratory that will serve as the facility that carries out the LymPro assay for CLIA launch. I wanted to touch on several aspects of this new relationship in today’s blog.
The ‘Fit for Purpose Flow Cytometry Assay Validation’ is the ‘Analytical Performance Package’ (APP) that the Company has been alluding to as the critical set of experiments required to demonstrate that we have the commercial-grade reproducibility required to support a successful diagnostic test. The reason the term ‘Fit for Purpose’ is used instead of ‘Analytical Performance Package,’ is because under CLIA there is no single standard required to demonstrate reproducibility, and therefore the analytical package being established is fit for the purpose of launching LymPro under CLIA. The ‘Fit for Purpose’ package requirements were developed by our diagnostic product development unit in close consultation with our corporate advisors and the team at Icon, who collectively have several decades of experience in launching CLIA-certified Laboratory Developed Tests (LDTs).
In Icon, we have found a tremendous group to work with as they are very experienced in flow cytometry and have a global distribution network. Icon has developed a tremendous niche in providing central laboratory and clinical trial supporting services to small and large biopharmaceutical companies, including several of the largest Alzheimer’s-focused therapeutic developers.
This arrangement is not a classic partnership, as Amarantus is maintaining all intellectual property rights to current and future versions of LymPro at the current time. This is a services agreement that gets the ball rolling on the CLIA process as we make progress on our ongoing LP-002 clinical study and puts Icon in a sub-contractor relationship with respect to LymPro. Icon will be providing central laboratory services to Amarantus in a fee-for-service arrangement, which is their primary business model. This services agreement extends over four years and covers LymPro’s central laboratory requirements under CLIA (under CLIA, only 1 laboratory facility can run a Laboratory Developed Test), in addition to consulting support for Eltoprazine’s further clinical development and our MANF program as we move it towards human trials. With this agreement, we also gain access to a global distribution network for LymPro, including central laboratories in Europe, Singapore, India and China that will allow LymPro to enter these new markets seamlessly through an already established distribution framework.
We are continuing to evaluate shareholder value creating arrangements for our diagnostics division, including a potential ‘spin-out’ or other business arrangements that would make strategic sense for the various LymPro and Amarantus stakeholders. We will not be giving additional details related to those possible arrangements in today’s business update call, as we are contractually prohibited from doing so.
We thank you for taking the time to read this blog, and look forward to interacting with our shareholders this afternoon during our business update call where we will describe in detail what we believe is the initial target market opportunity for LymPro, biopharmaceutical therapeutic trials.
With Warm Regards,
Gerald E. Commissiong
President & CEO
SMH - Lympro - what hooie
AJMHO
smart man
good fortunes to you
$MONI
DB just playing, testing resistance
wait till he locks & loads - MONI will surprise…!
BAF MONI
***** 5 STAR POST *****
resistance testing
will move on thin air...!
MONI...
SMH….!
$MONI
yo - that guy Daniel Borders that you discriminately call Chuckleface...
is actually out there working it - doing things - making things happen - putting the connections together
and making huge wins for his clients - and money for his followers
I was told long ago there are:
"3 Kinds of People in This World"
1.) those that make things happen
2.) those that watch things happen
3.) and those that wonder what the F happened
its quite apparent that you fall into the lowest category of that list
bring it brotha - we ain't seen shite from all your SEC legal law-suit phony, bogus & empty ramblings...!
BAF MONI - nuff said
Redspeed - nothing more than 'Chump-Change'
MOO pathetic
bring it ….
nuff said
BAF MONI
most long COVID symptoms clear up within a year, new research suggests
Dah - you can see all posts when opening the ADVFN website
even those who you have blocked
you should try it sometime
it might save you the embarrassment of wiping egg off your face pal...
MONI going to surprise - even you...!
AJMHO - BAF MONI
not going round and round with you
all this is - is simply Word Salad:
you can stickie that shite where ever you like ...!
it still doesn't change the TOMDF facts posted here:
or the other TOMDF facts posted here:
you can have your TOMDF shite pile all to yourself now...!
SMH - nuff said
MOO stoopid
sorry pal but have you blocked...
still believe we'll be pleasantly surprised
good fortunes to you regardless
$MONI
this is simply "NOT GOOD" by any means JoeyForksBolo
to be at this stage of 3-Bil. OS - yes that's "BILLION" folks - and still have no funding whatsoever for Tollo testing
is total & unequivocal reckless management, inept leadership, failed business planning, and was committed under flunky CEO fiduciary stewardship
this is a total disregard for all TOMDF shareholders - and Gerald Commissiong's failed CEO leadership actions should be held to their highest "professional legal standards"
Gerald Commissiong - twice failed flunky CEO should be "FIRED" - and an aggressive "Class Action" suit commenced immediately
there's simply no way in hell Todos will be able to raise enough Crowd Funding capital to survive - not with their $5-Mil/Qtr. accumulated losses. non-reporting OTC status, and gravely insufficient income for any of TOMDF's other misguided and catastrophic liabilities:
yeah - as a Stanford Financial Engineer earning $760k.Yr. - Gerald Commissiong is a complete failure, hack and the ultimate scam artist...
Greece and Israeli "Emergency Use Authorization" - my pearly right butt-check Gerald:
not once failed but twice failed - the best thing for Gerald Commissiong to do is "RESIGN" - and to resign now - without delay - its what a "REAL MAN" would do Gerald...!
MOO - disgusting
what if.....
the next announced BOD has a much much stronger bio than that of Scott Harmolin's...?
what if...
MONI's Pres. is announced in succession, after MONI's BOD - and has a much much stronger bio than either the BOD or Scott Harmolin's...?
this acquisition has taken a great deal of time, patience, planning, OTC regulatory compliance, background review, certified auditing, and is now its final phase - execution
all of this leads me to believe that something "BIG" has been planned and is in the works for MONI...!
these guys intuitively understand they have to get the pps well above $0.10...in order to attract large macro & micro investment funding
bottom line - the acquisition target members are no dummies...!
FO wants to go out on retirement with a splash and this acquisition may well provide it...!
BAF MONI
you’re lying
…because those other Dr’s did not mention Tollovid once in the conference that you referenced - which I posted the link for…
you should stop hyping and lying - Word Salad and Spin do you no justification.
nuff said
EOM
only Dr. Patrick Hanaway addressed Tollovid
not Dr Kara Parker, Dr Anna Sattah, Dr Michael Stone, Dr Kristine Burke, or Dr Kara Fitzgerald
these Tollovid results are not proof positive by any means, or even stellar for that matter:
https://www.drkarafitzgerald.com/2023/04/15/addressing-long-covid-data-driven-learning-model-for-practitioners-and-patients/
just saying for a friend - to keep it real - you know ?
SMH - nuff said
MOO hype
we know who the Shills, Dolts, & Touts are ...
in the TOMDF Back Office Boy Promo Room - eh JoeyForkitBollo on Reddit...?
or are you really Warp...lolzzzz
JoeForkeyBolo is a fake & phony - proof positive that he uses multiple fake aliases...!
SMH - nuff said
looks like"An Eye For An Eye" - eh Warp?
Moo butt-wipe
Sterling hands down - we got a seasoned CEO coming in to MONI
have to agree with you 100% …Scott has a plan
I expect him to come in like gang busters - hitting the deck running
audited financials - $50-Mil. Plus revenue on the books - could be as high as $70-Mil.
cant wait to see the new direction and what this new CEO has….!
BAF MONI
so mature Joey
your sophomoric reply exemplifies your true character “Warp”
keep buy those worthless TOMDF shares - Gerald loves you for it
14 followers - says it all
SMH - nuff said….!
MOO ignorant
we’ll spoken
unfortunately it was wasted words - falling on deaf ears…
TOMDF shills & touts come with ulterior motives - lolzzz
DB has brains - connections - and deep pockets…!
$MONI